Uncategorized

How to use patent expiry intelligence to reach biosimilar manufacturers at the moment their equipment decisions are live — not after they have already been made

In the fiercely competitive world of biosimilars, timing isn’t just everything — it’s the difference between capturing market share early or playing catch-up. Yet, many pharmaceutical companies and biosimilar manufacturers are still operating with a re…

How to use patent expiry intelligence to reach biosimilar manufacturers at the moment their equipment decisions are live — not after they have already been made Read Post »

Uncategorized

Sell Before the Drug Patent Expiration Cliff: A guide for Commercial & Market Access Vendors using anticipated Loss of Exclusivity dates to offer contracting strategy support before generic entry

The Hidden Power of the Patent Cliff: How Market Access Vendors Can Turn Imminent Generic Entry into a Strategic Advantage
Imagine this: your blockbuster drug is nearing its patent expiration. The clock is ticking, and the inevitable wave of generics i…

Sell Before the Drug Patent Expiration Cliff: A guide for Commercial & Market Access Vendors using anticipated Loss of Exclusivity dates to offer contracting strategy support before generic entry Read Post »

Uncategorized

Win the Patent War Before the Drug Goes Generic: How Paragraph IV Challenges and Pay-for-Delay Settlements Decide Who Gets Paid — and Who Gets Blocked

In the high-stakes world of pharmaceuticals, the battle over patent rights isn’t just a legal skirmish—it’s a multi-billion-dollar showdown that can determine the fate of innovation, access, and affordability. As drug companies race to protect their ma…

Win the Patent War Before the Drug Goes Generic: How Paragraph IV Challenges and Pay-for-Delay Settlements Decide Who Gets Paid — and Who Gets Blocked Read Post »

Biotechblog
Scroll to Top